Event JSON
{
"id": "3352646d0dfe83f562f3850a12f31bfbde7cae9bb4d97502f0097a1f3bd8f067",
"pubkey": "9f45137efe9d0c26b925c5214c9f8053e830f280d3d3a0cfa1a03c1436af0549",
"created_at": 1674499916,
"kind": 1,
"tags": [
[
"e",
"519417c9ab70827c1cc47123c9405cc0d8bdfb2474586947eeabb11609af614f"
],
[
"e",
"5be403eaad1e60d0c9f25300381c828c6aa43b7e6be9cda70fcdf05f6f594f17"
],
[
"p",
"5195320c049ccff15766e070413bbec1c021bca03ee022838724a8ffb680bf3a"
],
[
"p",
"2a9c6813e2cd86dced47191f24de8b1a05bf098bfcb0667b577a056e1495994e"
]
],
"content": "https://www.reuters.com/article/us-endocrine-disruptor-idUSBREA1O1U020140225",
"sig": "8afc8ad57f4b5acb555e8bdd233dbb840ee4e9cf25dc5133c2adfdb13fde58efa6cca14b9467144072eef7693f066b94d0e590fee2efbc8cc6748b0bdc3860f2"
}
